Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain
| dc.contributor.author | Hoefer, Melanie M. | |
| dc.contributor.author | Aichem, Annette | |
| dc.contributor.author | Knight, Andrew M. | |
| dc.contributor.author | Illges, Harald | |
| dc.date.accessioned | 2020-05-28T08:25:33Z | |
| dc.date.available | 2020-05-28T08:25:33Z | |
| dc.date.issued | 2008-04 | eng |
| dc.description.abstract | Ectodomain shedding is a mechanism that regulates numerous functions of cell surface proteins. The extracellular domain of the human complement receptor 2 (CR2/CD21) is released by proteolytic cleavage as a soluble protein through a variety of stimuli including the thiol antioxidants N-acetylcysteine (NAC) and glutathione (GSH), and the oxidant pervanadate (PV). In addition, PV mimics B cell antigen receptor (BCR) signaling. Here, we show that murine CD21 is shed upon those stimuli and that the cytoplasmic domain is an important modulator for CD21-shedding. B cells expressing a mutant CD21 cytoplasmic domain with only three amino acids (KHR) showed increased CD21-shedding and required lower stimuli concentrations. At lower PV concentrations, wildtype CD21 was up-regulated on the cell surface, whereas at higher PV concentrations the ectodomain was shed. These findings further indicate that GSH and NAC utilize different pathways than PV to activate CD21-shedding. Altogether, as pre-activated B cells express higher CD21 levels than resting mature B cells or fully activated and antigen-experienced B cells, we suggest CD21-shedding to be a mechanism to fine-tune B cell activation. | eng |
| dc.description.version | published | eng |
| dc.identifier.doi | 10.1016/j.molimm.2007.12.015 | eng |
| dc.identifier.pmid | 18295335 | eng |
| dc.identifier.uri | https://kops.uni-konstanz.de/handle/123456789/49713 | |
| dc.language.iso | eng | eng |
| dc.rights | terms-of-use | |
| dc.rights.uri | https://rightsstatements.org/page/InC/1.0/ | |
| dc.subject | B cell activation, Complement receptor 2/CD21, Glutathione, Pervanadate, Shedding | eng |
| dc.subject.ddc | 570 | eng |
| dc.title | Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain | eng |
| dc.type | JOURNAL_ARTICLE | eng |
| dspace.entity.type | Publication | |
| kops.citation.bibtex | @article{Hoefer2008-04Modul-49713,
year={2008},
doi={10.1016/j.molimm.2007.12.015},
title={Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain},
number={8},
volume={45},
issn={0161-5890},
journal={Molecular Immunology},
pages={2127--2137},
author={Hoefer, Melanie M. and Aichem, Annette and Knight, Andrew M. and Illges, Harald}
} | |
| kops.citation.iso690 | HOEFER, Melanie M., Annette AICHEM, Andrew M. KNIGHT, Harald ILLGES, 2008. Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain. In: Molecular Immunology. Elsevier. 2008, 45(8), pp. 2127-2137. ISSN 0161-5890. eISSN 1872-9142. Available under: doi: 10.1016/j.molimm.2007.12.015 | deu |
| kops.citation.iso690 | HOEFER, Melanie M., Annette AICHEM, Andrew M. KNIGHT, Harald ILLGES, 2008. Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain. In: Molecular Immunology. Elsevier. 2008, 45(8), pp. 2127-2137. ISSN 0161-5890. eISSN 1872-9142. Available under: doi: 10.1016/j.molimm.2007.12.015 | eng |
| kops.citation.rdf | <rdf:RDF
xmlns:dcterms="http://purl.org/dc/terms/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:bibo="http://purl.org/ontology/bibo/"
xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
xmlns:foaf="http://xmlns.com/foaf/0.1/"
xmlns:void="http://rdfs.org/ns/void#"
xmlns:xsd="http://www.w3.org/2001/XMLSchema#" >
<rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/49713">
<dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-05-28T08:25:33Z</dcterms:available>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<dcterms:issued>2008-04</dcterms:issued>
<dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
<dc:contributor>Hoefer, Melanie M.</dc:contributor>
<dc:creator>Aichem, Annette</dc:creator>
<dc:creator>Illges, Harald</dc:creator>
<dcterms:abstract xml:lang="eng">Ectodomain shedding is a mechanism that regulates numerous functions of cell surface proteins. The extracellular domain of the human complement receptor 2 (CR2/CD21) is released by proteolytic cleavage as a soluble protein through a variety of stimuli including the thiol antioxidants N-acetylcysteine (NAC) and glutathione (GSH), and the oxidant pervanadate (PV). In addition, PV mimics B cell antigen receptor (BCR) signaling. Here, we show that murine CD21 is shed upon those stimuli and that the cytoplasmic domain is an important modulator for CD21-shedding. B cells expressing a mutant CD21 cytoplasmic domain with only three amino acids (KHR) showed increased CD21-shedding and required lower stimuli concentrations. At lower PV concentrations, wildtype CD21 was up-regulated on the cell surface, whereas at higher PV concentrations the ectodomain was shed. These findings further indicate that GSH and NAC utilize different pathways than PV to activate CD21-shedding. Altogether, as pre-activated B cells express higher CD21 levels than resting mature B cells or fully activated and antigen-experienced B cells, we suggest CD21-shedding to be a mechanism to fine-tune B cell activation.</dcterms:abstract>
<void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
<dc:contributor>Knight, Andrew M.</dc:contributor>
<dcterms:title>Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain</dcterms:title>
<dc:creator>Hoefer, Melanie M.</dc:creator>
<dc:contributor>Aichem, Annette</dc:contributor>
<dc:language>eng</dc:language>
<dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-05-28T08:25:33Z</dc:date>
<dc:creator>Knight, Andrew M.</dc:creator>
<dc:rights>terms-of-use</dc:rights>
<dc:contributor>Illges, Harald</dc:contributor>
<bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/49713"/>
<foaf:homepage rdf:resource="http://localhost:8080/"/>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
</rdf:Description>
</rdf:RDF> | |
| kops.flag.isPeerReviewed | true | eng |
| kops.sourcefield | Molecular Immunology. Elsevier. 2008, <b>45</b>(8), pp. 2127-2137. ISSN 0161-5890. eISSN 1872-9142. Available under: doi: 10.1016/j.molimm.2007.12.015 | deu |
| kops.sourcefield.plain | Molecular Immunology. Elsevier. 2008, 45(8), pp. 2127-2137. ISSN 0161-5890. eISSN 1872-9142. Available under: doi: 10.1016/j.molimm.2007.12.015 | deu |
| kops.sourcefield.plain | Molecular Immunology. Elsevier. 2008, 45(8), pp. 2127-2137. ISSN 0161-5890. eISSN 1872-9142. Available under: doi: 10.1016/j.molimm.2007.12.015 | eng |
| relation.isAuthorOfPublication | 330796af-42ba-48a0-90d1-d3b196277661 | |
| relation.isAuthorOfPublication.latestForDiscovery | 330796af-42ba-48a0-90d1-d3b196277661 | |
| source.bibliographicInfo.fromPage | 2127 | eng |
| source.bibliographicInfo.issue | 8 | eng |
| source.bibliographicInfo.toPage | 2137 | eng |
| source.bibliographicInfo.volume | 45 | eng |
| source.identifier.eissn | 1872-9142 | eng |
| source.identifier.issn | 0161-5890 | eng |
| source.periodicalTitle | Molecular Immunology | eng |
| source.publisher | Elsevier | eng |